Bulk RNA-seq of Genetically Diverse Triple-Negative Breast Cancer Mouse Models Treated with Immunotherapy, Chemotherapy, Erlotinib, or Trametinib

To investigate the molecular determinants of response to therapy, we profiled 26 genetically diverse murine models of mammary cancer using bulk RNA sequencing. Tumors were harvested from mice that were either untreated or treated with immunotherapy (anti-PD-1 and anti-CTLA-4), chemotherapy (Carboplatin + Paclitaxel), EGFR inhibition (Erlotinib), or MEK inhibition (Trametinib) for 7 days. Each model represents a distinct transcriptional subtype and genetic background, enabling the assessment of intertumoral heterogeneity in treatment response. This dataset includes RNA-seq from 2-9 biological replicates per model per condition. Tumor samples were collected prior to or during treatment response assessment, and are accompanied by corresponding survival from similarly-treated tumors. All sequencing was performed on polyA-selected RNA using Illumina platforms.